Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Capital Expenditures: 2020-2025

Historic Capital Expenditures for Foghorn Therapeutics (FHTX) over the last 5 years, with Jun 2025 value amounting to $22,000.

  • Foghorn Therapeutics' Capital Expenditures rose 29.41% to $22,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $838,000, marking a year-over-year increase of 253.59%. This contributed to the annual value of $906,000 for FY2024, which is 25.98% down from last year.
  • Latest data reveals that Foghorn Therapeutics reported Capital Expenditures of $22,000 as of Q2 2025, which was down 21.43% from $28,000 recorded in Q1 2025.
  • In the past 5 years, Foghorn Therapeutics' Capital Expenditures ranged from a high of $1.8 million in Q1 2021 and a low of $17,000 during Q2 2024.
  • Its 3-year average for Capital Expenditures is $218,000, with a median of $91,500 in 2023.
  • As far as peak fluctuations go, Foghorn Therapeutics' Capital Expenditures slumped by 98.93% in 2021, and later soared by 1,194.59% in 2024.
  • Quarterly analysis of 5 years shows Foghorn Therapeutics' Capital Expenditures stood at $80,000 in 2021, then surged by 236.25% to $269,000 in 2022, then plummeted by 86.25% to $37,000 in 2023, then soared by 1,194.59% to $479,000 in 2024, then increased by 29.41% to $22,000 in 2025.
  • Its Capital Expenditures stands at $22,000 for Q2 2025, versus $28,000 for Q1 2025 and $479,000 for Q4 2024.